Tiragolumab 是一种与 T 细胞免疫球蛋白和 ITIM 结构域 (TIGIT) 结合的免疫检查点抑制剂。Tiragolumab 单独或与 PD-L1 抑制剂 Atezolizumab 联合使用，可能对多种实体恶性肿瘤有效，尤其是非小细胞肺癌。
| 生物活性 | Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with thePD-L1inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lungcancer[1][2]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
